Anatara Lifesciences Ltd (AU:ANR) has released an update.
Anatara Lifesciences Ltd has achieved positive momentum in its Stage 2 clinical trial for the GaRP-IBS treatment, with 36 participants already enrolled and more in the final screening phase. The company has expanded recruitment efforts by adding trial sites in Adelaide and Queensland, with strong community interest and active participation. Though the timeline for results has been extended, the completion of recruitment is expected by Q4 CY2024, with headline results anticipated in Q1 CY2025.
For further insights into AU:ANR stock, check out TipRanks’ Stock Analysis page.
